### Sunday 28 April 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>MAIN HALL</th>
<th>WILLEM BURGER HALL</th>
<th>JURRIAANSE HALL</th>
<th>MEES/FORTIS HALL</th>
<th>VAN CAPELLEN HALL</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.30-20.00</td>
<td>PRE-REGISTRATION</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30-19.00</td>
<td><strong>Interactive session</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fake Virology and Vaccines: a matter of perspective?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maarten Keulemans: Fake Virology and Vaccines: a journalistic perspective</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Daan Remarque: Fake Virology and Vaccines: a marketing perspective</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Roel Coutinho: Fake Virology and Vaccines: a public health perspective</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.00-20.30</td>
<td>WELCOME RECEPTION</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Monday 29 April 2019

#### MAIN HALL

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-10.30</td>
<td>Plenary 1</td>
<td>Emerging viruses at the human animal interface</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>Session 1</td>
<td></td>
</tr>
<tr>
<td>12.30-14.00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14.00-15.30</td>
<td>Session 2</td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

#### WILLEM BURGER HALL

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30-11.00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>Session 1</td>
<td>RVs and receptors + glycochemistry</td>
</tr>
<tr>
<td>12.30-14.00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14.00-15.30</td>
<td>Session 2</td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

#### JURRIAANSE HALL

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30-11.00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>Session 1</td>
<td></td>
</tr>
<tr>
<td>12.30-14.00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14.00-15.30</td>
<td>Session 2</td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

#### MEES/FORTIS HALL

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30-11.00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>Session 1</td>
<td></td>
</tr>
<tr>
<td>12.30-14.00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14.00-15.30</td>
<td>Session 2</td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

#### VAN CAPPELEN HALL

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30-11.00</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>Session 1</td>
<td></td>
</tr>
<tr>
<td>12.30-14.00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14.00-15.30</td>
<td>Session 2</td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

#### POSTER WALK 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00-17.30</td>
<td>Plenary 2</td>
<td>The development of novel RNA virus detection strategies</td>
</tr>
<tr>
<td>17.30-19.30</td>
<td>Posters 1</td>
<td></td>
</tr>
</tbody>
</table>

---

**FULL SCHEDULE**

**SESSION 1**

**1A: Viral Pathogenesis**

- **Viruses and receptors + glycochemistry**
  - Host-virus interactions and viral invasion mechanisms
  - Host-virus interactions and viral invasion mechanisms

- **Viruses and receptors + glycochemistry**
  - Host-virus interactions and viral invasion mechanisms
  - Host-virus interactions and viral invasion mechanisms

**1B: Emerging viruses at the human animal interface**

- **Emerging viruses at the human animal interface**
  - Emerging viruses at the human animal interface
  - Emerging viruses at the human animal interface

**1C: Viruses and receptors + glycochemistry**

- **Viruses and receptors + glycochemistry**
  - Viruses and receptors + glycochemistry
  - Viruses and receptors + glycochemistry

**1D: Latent and persistent infections**

- **Latent and persistent infections**
  - Latent and persistent infections
  - Latent and persistent infections

**SESSION 2**

**2A: Antiviral Immune-metabolism**

- **Antiviral Immune-metabolism**
  - Antiviral Immune-metabolism
  - Antiviral Immune-metabolism

**2B: Immunity**

- **Immunity**
  - Immunity
  - Immunity

**2C: Virulence**

- **Virulence**
  - Virulence
  - Virulence

**2D: Viruses and cancer**

- **Viruses and cancer**
  - Viruses and cancer
  - Viruses and cancer

---

**EVENTS**

**ONE HEALTH** Emerging viruses at the human animal interface

**Breaks**

- 10.30-11.00
- 11.00-12.30
- 12.30-14.00
- 14.00-15.30
- 15.30-16.00

**Lunch**

**Plenary Sessions**

- Plenary 1: Emerging viruses at the human animal interface, chairs: Noël Tordo & Martijn van Hemert
- Plenary 2: Evolution of emerging plant RNA viruses, chairs: Ron Fouchier & Bjorn Koel

**Posters**

- Posters 1: Emerging viruses at the human animal interface, chairs: Ron Fouchier & Bjorn Koel
### Tuesday 30 April 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>Session 2</th>
<th>Session 3</th>
<th>Session 4</th>
<th>Session 5</th>
<th>Session 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30-10.30</td>
<td><em>Plenary 3</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30-11.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30-14.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-15.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00-17.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30-19.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.00-00.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Main Hall**

**Main Hall**

### Plenary 3

- **Ben Berkhour** towards an HIV cure using Crispr-Cas technology
- **John Carr** Modeling and manipulation of aphid-mediated spread of non-persistently transmitted viruses
- **Rob Hoeben** Exploiting Reovirus Plasticity for Enhancing Antitumor Efficacy in Oncolytic Applications

**Session 3**

- **Viral diversity in global urban sewage, David Willem Burger Hall**
- **Enteric Virus diversity in sewages collected during last 20 years, Jurriaanse Hall**
- **The Viral Protein Corona Directs Viral Pathogenesis and the Structural Biology Perspective, Jurriaanse Hall**

**Session 6**

- **Three-dimensional co-cultivation of cells from different species and tissues in a novel bioprinted array as a diagnostic tool for viruses, Markus Neumann**
- **Common themes in the architecture and function of the influenza virus replication organelle, Síri Skúlason**

**Session 4**

- **A single nested PCR method for full length dengue virus genome amplification followed by long read next generation sequencing, Cherevate Bolde**
- **Specific serology in areas of flavivirus co-circulation, Sebastian Albert**
- ***Break***

**Session 5**

- **Three-dimensional co-cultivation of cells from different species and tissues in a novel bioprinted array as a diagnostic tool for viruses, Markus Neumann**
- **Common themes in the architecture and function of the influenza virus replication organelle, Síri Skúlason**

**Session 2**

- **The pathogenesis of measles skin rash, Brigitta Laksono**
- **Emergence of the Zika virus Asian lineage in Angola, S. Hill**
- **Novel DENV and ZIKV subunit vaccine candidates by transkingdom interactions in the gut: enteric viruses, bacteria, and the host, Christiane Wobus**

**Session 1**

- **In vitro modeling of patient-specific susceptibility to neurotropic flavivirus infection by comparing different stages of MERS coronavirus entry, Berend Jan Bosch**
- **Protective human monoclonal antibodies targeting non-persistently transmitted viruses**, **Adinda Kok**
- **Vaccines and broadly neutralising antibodies**, **Felix Rey & Hanse Langedijk**

**Poster Sessions**

- **Poster award**
- **20.00-00.00 Congress Dinner**

**Plenary 4**

- **Arboviruses and insect vectors: a never ending dance, Anna-Bella Failloux**
- **Zika virus: where do we stand?, Xavier De Lamballerie**
- **Flavivirus-host interactions, Anna-Bella Failloux**

**Session 6**

- **Vaccines and broadly neutralising antibodies**, **Felix Rey & Hanse Langedijk**
- **THERAPEUTIC VIROLOGY; Gene therapy and gene editing; Oncolytic Viro-Immunotherapies, chairs: Thomas Mertens & Bernadette van den Hoogen**

**Session 3**

- **Comparative pathogenesis**, **The human upper respiratory tract epithelium is a target state of the art, Thijs Kuiken**
- **Comparative pathogenesis**, **Silvia Ricetti**

**Session 2**

- **In vitro modeling of patient-specific susceptibility to neurotropic flavivirus infection by using induced pluripotent stem cells, Berend Jan Bosch**
- **Protective human monoclonal antibodies targeting different stages of MERS coronavirus entry, Adinda Kok**
- **Structural virology**, **Santiago Elena & Richard Kormelink**

**Session 1**

- **Comparative pathogenesis**, **The human upper respiratory tract epithelium is a target state of the art, Thijs Kuiken**
- **Comparative pathogenesis**, **Silvia Ricetti**

**Session 5**

- **Vaccines and broadly neutralising antibodies**, **Felix Rey & Hanse Langedijk**
- **Structural virology**, **Santiago Elena & Richard Kormelink**

**Session 4**

- **Comparative pathogenesis**, **The human upper respiratory tract epithelium is a target state of the art, Thijs Kuiken**
- **Comparative pathogenesis**, **Silvia Ricetti**

**Session 3**

- **Comparative pathogenesis**, **The human upper respiratory tract epithelium is a target state of the art, Thijs Kuiken**
- **Comparative pathogenesis**, **Silvia Ricetti**

**Session 2**

- **Comparative pathogenesis**, **The human upper respiratory tract epithelium is a target state of the art, Thijs Kuiken**
- **Comparative pathogenesis**, **Silvia Ricetti**

**Session 1**

- **Comparative pathogenesis**, **The human upper respiratory tract epithelium is a target state of the art, Thijs Kuiken**
- **Comparative pathogenesis**, **Silvia Ricetti**
| Slot 1 | Bart Haagmans | Vaccines against emerging viruses |
| Slot 2 | Marie-Paule Kieny | Vaccine development in a public health emergency |
| Slot 3 | Rogier Sanders | Inducing HIV-1 neutralizing antibodies by stabilized native-like envelope trimers |

**VACCINES**

Chairs: Thomas Mettenleiter & Kander de Haan

---

### 10.00-10.30

**Plenary 5**

**5A: Evolution**

Colin Russell & Nancy Beerens

**5B: Congenital and neonatal infections**

Tatjana Avsic-Zupanc & Pieter Fraaij

**5C: Focus on BSL4 pathogens**

Jonas Schmidt-Chanasit & Barry Rockx

**5D: Focus on veterinary diseases**

Massimo Palmarini & Paul Wichgers Schreur

---

### 12.00-13.30

**LUNCH**

---

### 13.30-15.15

**Plenary 6**

**58** Block and Kill: a new approach to a functional cure for HIV, preventing HIV reactivation and inducing selective apoptosis of HIV-infected cells, Alfredo Garzino-Demo

**59** Efficient HIV latency reversal with immune checkpoint blockade in a primary T-cell latency model, Renee van der Skuis

**60** Results of a phase 2 Clinical Trial to assess safety and efficacy of Myrcludex B in combination with PegIFNa in HBV/HBV co-infected patients, Stephan Urban

---

### 10.00-10.30

**Session 5**

**5A: Evolution**

Colin Russell & Nancy Beerens

**5B: Congenital and neonatal infections**

Tatjana Avsic-Zupanc & Pieter Fraaij

**5C: Focus on BSL4 pathogens**

Jonas Schmidt-Chanasit & Barry Rockx

**5D: Focus on veterinary diseases**

Massimo Palmarini & Paul Wichgers Schreur

---

### 12.00-13.30

**LUNCH**

---

### 13.30-15.15

**Plenary 6**

**58** Block and Kill: a new approach to a functional cure for HIV, preventing HIV reactivation and inducing selective apoptosis of HIV-infected cells, Alfredo Garzino-Demo

**59** Efficient HIV latency reversal with immune checkpoint blockade in a primary T-cell latency model, Renee van der Skuis

**60** Results of a phase 2 Clinical Trial to assess safety and efficacy of Myrcludex B in combination with PegIFNa in HBV/HBV co-infected patients, Stephan Urban